1232059-97-0

Basic information

• Product Name: trans-4-AMino-1-Boc-3-Methoxypiperidine
• Synonyms: trans-4-AMino-1-Boc-3-Methoxypiperidine;trans-4-AMino-1-Boc-3-Met...;trans-tert-Butyl 4-amino-3-methoxypiperidine-1-carboxylate
• CAS NO: 1232059-97-0
• Molecular Formula: C11H22N2O3
• Molecular Weight: 230.30398
• Mol File: 1232059-97-0.mol

Chemical Properties

• Boiling Point: 306.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.07±0.1 g/cm3(Predicted)
• PKA: 9.42±0.40(Predicted)
• CAS DataBase Reference: trans-4-AMino-1-Boc-3-Methoxypiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-AMino-1-Boc-3-Methoxypiperidine(1232059-97-0)
• EPA Substance Registry System: trans-4-AMino-1-Boc-3-Methoxypiperidine(1232059-97-0)

Safety Data

• Hazardous Substances Data: 1232059-97-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Trans-4-Amino-1-Boc-3-Methoxypiperidine is used as a pharmaceutical intermediate for the production of various drugs. Its significance in medicinal chemistry is attributed to its ability to serve as a building block in the synthesis of new therapeutic agents, contributing to the development of innovative treatments and medications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Trans-4-Amino-1-Boc-3-Methoxypiperidine is used as a key component in the synthesis of novel compounds with potential therapeutic applications. Its reactivity and structural features make it an essential tool for researchers in the design and development of new drugs, enhancing the possibilities for medical advancements.

Upstream product

• 1171124-68-7 tert-butyl cis(±)-4-amino-3-methoxypiperidine-1-carboxylate 
• 1188265-31-7 3-methoxy-4-oxopiperidine-1-carboxylic acid t-butyl ester 
• 942945-28-0 1,1-dimethylethyl 3,4,4-tris(methyloxy)-1-piperidinecarboxylate 
• 841286-80-4 (±)-tert-butyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1171125-92-0 tert-butyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate 

Relevant articles and documents

N-PHOSPHONOXYMETHYL PRODRUGS OF HYDROXYALKYL THIADIAZOLE DERIVATIVES

There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and s

HYDROXYALKYL THIADIAZOLE DERIVATIVES

Problem to be solved. There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and safety profile amenable to human use. Solution to the Problem. As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit, possess excellent solubility and safety profile for use in human for the treatment of bacterial infectious diseases.

Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors

ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphthyridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.

ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES

This invention relates to pyrrolopyrimidine derivatives of formula (I): where R1, X, p, R4, R2and R3are as defined herein, and their use as pharmaceuticals.

IMIDAZOLE CARBONYL COMPOUND

To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.

CONDENSED PYRIDINE COMPOUND

The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention. More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).